Epigenetics and Genomics Markets Set for Major Growth Through 2035

The global epigenetics drugs and diagnostic technologies market was calculated at USD 20.17 billion in 2025 and is predicted to increase from USD 23.13 billion in 2026 to approximately USD 79.03 billion by 2035, expanding at a CAGR of 14.63% from 2026 to 2035. The global genomics in cancer care market was estimated at USD 24.39 billion in 2025 and is predicted to increase from USD 28.32 billion in 2026 to approximately USD 108.69 billion by 2035, expanding at a CAGR of 28.32% from 2026 to 2035.

The growing awareness of gene expression techniques, their role in disease treatment, and evolving regulatory practices drive the epigenetics market. The increasing need for precision medicine and targeted therapies is driving investment in epigenetics research and clinical practice. The genomics in cancer care market is gaining strong momentum as oncology shifts toward precision and personalized medicine. Advances in next-generation sequencing, biomarker discovery, and liquid biopsy are improving early detection and treatment decisions.

North America dominated the epigenetics drugs and diagnostic technologies market with a share of approximately 42% in 2025. North America led the genomics in cancer care market with a share of approximately 39% in 2025. Asia-Pacific is expected to grow at the fastest CAGR in both markets during the forecast period.

In the epigenetics market, the therapeutic drugs segment held a dominant position with a share of approximately 62% in 2025, while the diagnostics and companion tests segment is expected to grow at the fastest CAGR between 2026 and 2035. By therapeutic modality, the small-molecule epigenetic modulators segment led the global market with a share of approximately 55% in 2025, while the oligonucleotide/RNA-targeting approaches segment is expected to grow with the highest CAGR during the studied years.

By indication/therapeutic area in epigenetics, the oncology (solid tumors) segment dominated the global market with a share of approximately 48% in 2025, while the neurological and CNS disorders segment is expected to expand rapidly in the market with a CAGR in the coming years. By diagnostic type, the tissue-based methylation/histology assays segment held a major revenue share of approximately 41% in the epigenetics drugs and diagnostic technologies market in 2025, while the liquid biopsy/circulating DNA methylation panels segment is expected to gain the highest market share between 2026 and 2035.

In the genomics in cancer care market, the next-generation sequencing (NGS) segment held a dominant revenue share of approximately 48% in 2025. By application, the cancer diagnosis and early detection segment dominated the market with a share of approximately 32% in 2025, while the therapy monitoring/minimal residual disease (MRD) segment is expected to expand at the fastest CAGR from 2026 to 2035.

By end-user in the epigenetics market, the hospitals and oncology centers segment contributed the biggest revenue share of approximately 44% in 2025, while the pharmaceutical/biotech companies segment is expected to account for the highest growth in the predicted timeframe. In the genomics market, the hospitals and cancer centers segment held a dominant share of approximately 42% in 2025, while the academic and research institutes segment is expected to grow with the highest CAGR in the coming years.

Artificial intelligence is changing epigenetics by facilitating the analysis of complex genomic and epigenomic data in a short time. Machine learning algorithms can be used to determine epigenetic biomarkers and predict therapeutic response with increased precision. AI is used to discover the targets and is implemented in the identification of concealed patterns in chromatin modification data. It also assists in the optimization of drugs and the stratification of patients in clinical trials.

AI is reshaping genomics in cancer care by enabling faster, more accurate analysis of complex genomic datasets and improving clinical decision-making. Advanced algorithms support precise mutation detection, variant interpretation, and biomarker identification from next-generation sequencing data. AI integration helps oncologists match patients with targeted therapies, predict treatment response, and monitor disease progression through real-time insights. It also accelerates drug discovery and clinical research by uncovering hidden genetic patterns.

NGS continues to be fundamental to genomics in cancer care, enabling comprehensive analysis of tumor genomes faster and more affordably. Clinicians and researchers increasingly use NGS for whole-genome, whole-exome, and targeted gene panel sequencing, which improves detection of actionable mutations and supports personalized treatment decisions across diverse cancer types. Higher throughput and lower costs are making NGS an essential tool in routine oncology practice.

Liquid biopsy technologies that analyze circulating tumor DNA (ctDNA) are transforming cancer screening and disease monitoring. Unlike traditional tissue biopsies, these blood-based tests are less invasive, allow frequent sampling, and offer real-time insights into tumor evolution, treatment response, and minimal residual disease. This trend improves patient compliance and enables earlier intervention with tailored therapies.

By clinical development stage (therapeutics) in the epigenetics market, the phase II segment held a major revenue share of approximately 34% in 2025, while the phase I/preclinical segment is expected to show the fastest growth over the forecast period. By reimbursement/commercial model, the prescription/reimbursed therapeutics segment held a major revenue share of approximately 57% in 2025, while the subscription/software-as-a-service segment is expected to gain the highest market share between 2026 and 2035.

By cancer type in the genomics market, the breast cancer segment held a dominant revenue share of approximately 26% in 2025, while the hematologic/blood cancers segment is expected to expand rapidly over the studied period. The market includes technologies, tools, and services that use genomic sequencing, gene expression profiling, mutation analysis, and bioinformatics to support cancer diagnosis, prognosis, treatment selection, therapy monitoring, and personalized medicine.